Published in Semin Nucl Med on January 01, 2002
Planar and SPECT imaging in the era of PET and PET-CT: can it survive the test of time? Eur J Nucl Med Mol Imaging (2008) 2.74
Noninvasive pulmonary [18F]-2-fluoro-deoxy-D-glucose positron emission tomography correlates with bactericidal activity of tuberculosis drug treatment. Antimicrob Agents Chemother (2009) 2.18
Limitations of PET for imaging lymphoma. Eur J Nucl Med Mol Imaging (2003) 1.34
Takayasu arteritis--advances in diagnosis and management. Nat Rev Rheumatol (2010) 1.29
Non-invasive imaging in the diagnosis and management of Takayasu's arteritis. Ann Rheum Dis (2004) 1.21
Role of modern imaging techniques for diagnosis of infection in the era of 18F-fluorodeoxyglucose positron emission tomography. Clin Microbiol Rev (2008) 1.16
FDG-PET is an effective imaging modality to detect and quantify age-related atherosclerosis in large arteries. Eur J Nucl Med Mol Imaging (2007) 1.13
Baastrup's disease (kissing spine) demonstrated by FDG PET/CT. Skeletal Radiol (2007) 1.13
Real time monitoring of biomaterial-mediated inflammatory responses via macrophage-targeting NIR nanoprobes. Biomaterials (2011) 0.98
Expanding role of 18F-fluoro-D-deoxyglucose PET and PET/CT in spinal infections. Eur Spine J (2010) 0.98
Radioiodinated DPA-713 imaging correlates with bactericidal activity of tuberculosis treatments in mice. Antimicrob Agents Chemother (2014) 0.96
PET-CT enteroclysis: a new technique for evaluation of inflammatory diseases of the intestine. Eur J Nucl Med Mol Imaging (2007) 0.92
18F-FDG PET/CT for diagnosing infectious complications in patients with severe neutropenia after intensive chemotherapy for haematological malignancy or stem cell transplantation. Eur J Nucl Med Mol Imaging (2011) 0.92
PET/MR imaging of the pelvis in the presence of endoprostheses: reducing image artifacts and increasing accuracy through inpainting. Eur J Nucl Med Mol Imaging (2013) 0.91
Emergence of molecular imaging of aortic aneurysm: implications for risk stratification and management. J Nucl Cardiol (2014) 0.91
In vitro human leukocyte labeling with (64)Cu: an intraindividual comparison with (111)In-oxine and (18)F-FDG. Nucl Med Biol (2009) 0.90
The value of (18)FDG-PET for the detection of infected hip prosthesis. Eur J Nucl Med Mol Imaging (2003) 0.89
18FDG PET-CT imaging detects arterial inflammation and early atherosclerosis in HIV-infected adults with cardiovascular disease risk factors. J Inflamm (Lond) (2012) 0.89
Noninvasive molecular imaging of tuberculosis-associated inflammation with radioiodinated DPA-713. J Infect Dis (2013) 0.89
Application of (1)h NMR spectroscopy-based metabolomics to sera of tuberculosis patients. J Proteome Res (2013) 0.89
¹⁸F-FDG PET/CT in the diagnosis of occult bacterial infections in children. Eur J Pediatr (2013) 0.88
Unusual positron emission tomography findings in pulmonary amyloidosis: a case report. J Cardiothorac Surg (2006) 0.87
FDG-PET in infectious and inflammatory disease. Eur J Nucl Med Mol Imaging (2003) 0.87
Variety and complexity of fluorine-18-labelled fluoro-2-deoxy-D-glucose accumulations in the oral cavity of patients with oral cancers. Dentomaxillofac Radiol (2013) 0.85
Nuclear medicine imaging of infection in cancer patients (with emphasis on FDG-PET). Oncologist (2011) 0.84
Nuclear imaging: a powerful novel approach for tuberculosis. Nucl Med Biol (2014) 0.84
Hypoxia, blood flow and metabolism in squamous-cell carcinoma of the head and neck: correlations between multiple immunohistochemical parameters and PET. BMC Cancer (2014) 0.83
Antimicrobial peptides as infection imaging agents: better than radiolabeled antibiotics. Int J Pept (2012) 0.83
¹⁸F-FDG uptake by spleen helps rapidly predict the dose level after total body irradiation in a Tibetan minipig model. Eur Radiol (2012) 0.82
Staging with PET and the "Will Rogers" effect: redefining prognosis and survival in patients with cancer. Eur J Nucl Med Mol Imaging (2008) 0.81
Uptake of aortic 18F-FDG is correlated with low-density lipoprotein cholesterol and leptin in a general population. PLoS One (2014) 0.81
Functional imaging of infection: conventional nuclear medicine agents and the expanding role of 18-F-FDG PET. Pediatr Radiol (2011) 0.80
Fatal hemorrhage induced by subtilase cytotoxin from Shiga-toxigenic Escherichia coli. Microb Pathog (2011) 0.80
New Intraspinal cause of physiological FDG uptake. Indian J Nucl Med (2010) 0.80
Clinical feasibility of two-step streptavidin/111In-biotin scintigraphy in patients with suspected vertebral osteomyelitis. Eur J Nucl Med Mol Imaging (2004) 0.78
(18)F-FDG microPET imaging differentiates between septic and aseptic wound healing after orthopedic implant placement: a longitudinal study of an implant osteomyelitis in the rabbit tibia. Acta Orthop (2014) 0.78
Early-onset childhood sarcoidosis with incidental multiple enchondromatosis. J Korean Med Sci (2011) 0.78
[Large vessel vasculitis as cause of fever of unknown origin (FUO) or systemic inflammation. Diagnosis using 18-F-fluor-2-deoxy-D-glucose positron emission tomography ((18)F-FDG-PET)]. Z Rheumatol (2005) 0.77
"The Great Mimicker": An Unusual Etiology of Cytopenia, Diffuse Lymphadenopathy, and Massive Splenomegaly. Case Rep Med (2015) 0.77
Postsurgical atypical F-18 fluorodeoxyglucose positron emission tomography uptake. Clin Nucl Med (2009) 0.77
PET/CT demonstrates increased myocardial FDG uptake following irradiation therapy. Eur J Nucl Med Mol Imaging (2007) 0.77
Voxel-based dual-time 18F-FDG parametric imaging for rectal cancer: differentiation of residual tumor from postchemoradiotherapy changes. Nucl Med Commun (2013) 0.76
18FDG imaging of giant cell arteritis: usefulness of whole-body plus brain PET. Eur J Nucl Med Mol Imaging (2004) 0.76
Efficacy of vancomycin-releasing biodegradable poly(lactide-co-glycolide) antibiotics beads for treatment of experimental bone infection due to Staphylococcus aureus. J Orthop Surg Res (2016) 0.75
An atypical sarcoidosis involvement in FDG PET/CT: A case report. Medicine (Baltimore) (2016) 0.75
Correlation between fluorodeoxyglucose positron emission tomography and magnetic resonance imaging findings of non-suppurative meningoencephalitis in 5 dogs. Can Vet J (2010) 0.75
Pulmonary Tuberculosis Confirmed by Percutaneous Transthoracic Needle Biopsy: Analysis of CT Findings and Review of Correlations with Underlying Lung Disease. Balkan Med J (2014) 0.75
Pitfalls in interpretation of FDG PET/CT: Septic pulmonary emboli mimicking metastases in a case of gastric carcinoma. Indian J Radiol Imaging (2017) 0.75
Dynamic FDG-PET Imaging to Differentiate Malignancies from Inflammation in Subcutaneous and In Situ Mouse Model for Non-Small Cell Lung Carcinoma (NSCLC). PLoS One (2015) 0.75
FDG-PET imaging to detect and characterize infectious disorders; an unavoidable path for the foreseeable future. Eur J Nucl Med Mol Imaging (2017) 0.75
Uncommon osseous involvement in multisystemic sarcoidosis. Ann Saudi Med (2009) 0.75
Positron emission tomography imaging in sarcoidosis. World J Nucl Med (2013) 0.75
Disseminated tuberculosis mimicking ankylosing spondylitis. Case Rep Rheumatol (2011) 0.75
In vivo evaluation of TNF-alpha in the lungs of patients affected by sarcoidosis. Biomed Res Int (2015) 0.75
Growing applications of FDG PET-CT imaging in non-oncologic conditions. J Biomed Res (2015) 0.75
Comparison of Visceral Fat Measures with Cardiometabolic Risk Factors in Healthy Adults. PLoS One (2016) 0.75
(18)F-FDG uptake in the stomach on screening PET/CT: value for predicting Helicobacter pylori infection and chronic atrophic gastritis. BMC Med Imaging (2016) 0.75
Unexpected FDG-PET uptake in the gastrointestinal tract: endoscopic and histopathological correlations. World J Gastroenterol (2014) 0.75
Primary Pulmonary Lymphoepithelioma-like Carcinoma on FDG PET/CT. Nucl Med Mol Imaging (2016) 0.75
Evaluation of Avulsion-Induced Neuropathology in Rat Spinal Cords with 18F-FDG Micro-PET/CT. PLoS One (2015) 0.75
Unsuspected Active Sarcoidosis Diagnosed by 18F-FDG PET/CT During the Search for a Primary Tumour in a Patient with Bone Lesions. Nucl Med Mol Imaging (2013) 0.75
Increased 18F-FDG uptake suggests synovial inflammatory reaction with osteoarthritis: preliminary in-vivo results in humans. Nucl Med Commun (2015) 0.75
18F-FDG PET/CT evaluation of children and young adults with suspected spinal fusion hardware infection. Pediatr Radiol (2013) 0.75
Multifocal lesions with pancreatic atrophy in IgG4-related autoimmune pancreatitis: report of a case. Surg Today (2013) 0.75
Dielectric imaging for differentiation between cancer and inflammation in vivo. Sci Rep (2017) 0.75
Diagnostic value of 18F-fluorodeoxyglucose uptake parameters to differentiate rheumatoid arthritis from other types of arthritis. Medicine (Baltimore) (2017) 0.75
Necrotic pseudotumor caused by a metal-on-metal total hip prosthesis: imaging characteristics on (18)F-FDG PET/CT and correlative imaging. Skeletal Radiol (2011) 0.75
The Role of Nuclear Medicine in the Staging and Management of Human Immune Deficiency Virus Infection and Associated Diseases. Nucl Med Mol Imaging (2016) 0.75
Akt stimulates aerobic glycolysis in cancer cells. Cancer Res (2004) 9.35
Treatment-responsive limbic encephalitis identified by neuropil antibodies: MRI and PET correlates. Brain (2005) 6.81
Skeletal PET with 18F-fluoride: applying new technology to an old tracer. J Nucl Med (2007) 3.08
Comparison of 123I scintigraphy at 5 and 24 hours in patients with differentiated thyroid cancer. J Nucl Med (2002) 2.05
Impact of FDG PET on the preoperative staging of newly diagnosed breast cancer. Eur J Nucl Med Mol Imaging (2007) 1.93
Diagnosis and localization of focal congenital hyperinsulinism by 18F-fluorodopa PET scan. J Pediatr (2007) 1.92
Systemic and vascular inflammation in patients with moderate to severe psoriasis as measured by [18F]-fluorodeoxyglucose positron emission tomography-computed tomography (FDG-PET/CT): a pilot study. Arch Dermatol (2011) 1.88
The SNMMI practice guideline for therapy of thyroid disease with 131I 3.0. J Nucl Med (2012) 1.84
Mitotic rate as a predictor of sentinel lymph node positivity in patients with thin melanomas. Ann Surg Oncol (2005) 1.84
Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response? J Nucl Med (2003) 1.71
Utility of FDG-PET scanning in lymphoma by WHO classification. Blood (2003) 1.69
Dynamic changes of FDG uptake and clearance in normal tissues. Mol Imaging Biol (2013) 1.66
PET in the management of urologic malignancies. Radiol Clin North Am (2004) 1.62
Dual time point 18F-FDG PET for the evaluation of pulmonary nodules. J Nucl Med (2002) 1.60
Paraneoplastic cerebellar degeneration: Yo-expressing tumor revealed after a 5-year follow-up with FDG-PET. J Neurol Sci (2006) 1.57
Assessment of atherosclerosis in large vessel walls: A comprehensive review of FDG-PET/CT image acquisition protocols and methods for uptake quantification. J Nucl Cardiol (2015) 1.53
18F-FDG uptake in lung, breast, and colon cancers: molecular biology correlates and disease characterization. J Nucl Med (2009) 1.52
Functional imaging of inflammatory diseases using nuclear medicine techniques. Semin Nucl Med (2009) 1.51
Age-related changes in the metabolic activity and distribution of the red marrow as demonstrated by 2-deoxy-2-[F-18]fluoro-D-glucose-positron emission tomography. Mol Imaging Biol (2007) 1.48
Is PET-CT the only option? Eur J Nucl Med Mol Imaging (2007) 1.48
The effects of estrogen, progesterone, and C-erbB-2 receptor states on 18F-FDG uptake of primary breast cancer lesions. J Nucl Med (2007) 1.47
Enhanced marrow [18F]fluorodeoxyglucose uptake related to myeloid hyperplasia in Hodgkin's lymphoma can simulate lymphoma involvement in marrow. Clin Lymphoma (2004) 1.44
Critical considerations on the combined use of ¹⁸F-FDG and ¹⁸F-fluoride for PET assessment of metastatic bone disease. Eur J Nucl Med Mol Imaging (2013) 1.44
Positron emission tomography as a diagnostic tool in infection: present role and future possibilities. Semin Nucl Med (2009) 1.44
Metabolic activity of the tongue in obstructive sleep apnea. A novel application of FDG positron emission tomography imaging. Am J Respir Crit Care Med (2014) 1.43
A pilot study to assess the utility of SPECT/CT-based lymph node imaging to localize lymph nodes that drain the arm in patients undergoing treatment for breast cancer. Breast Cancer Res Treat (2009) 1.42
Potential of dual time point FDG-PET imaging in differentiating malignant from benign pleural disease. Mol Imaging Biol (2009) 1.42
Direct comparison of fluorodeoxyglucose positron emission tomography and arterial spin labeling magnetic resonance imaging in Alzheimer's disease. Alzheimers Dement (2011) 1.41
Applications of fluorodeoxyglucose-PET imaging in the detection of infection and inflammation and other benign disorders. Radiol Clin North Am (2005) 1.40
FDG-PET imaging in primary bilateral adrenal lymphoma: a case report and review of the literature. Clin Nucl Med (2005) 1.38
When should we recommend use of dual time-point and delayed time-point imaging techniques in FDG PET? Eur J Nucl Med Mol Imaging (2013) 1.37
Use of a corrected standardized uptake value based on the lesion size on CT permits accurate characterization of lung nodules on FDG-PET. Eur J Nucl Med Mol Imaging (2002) 1.37
Potential of dual-time-point imaging to improve breast cancer diagnosis with (18)F-FDG PET. J Nucl Med (2005) 1.33
Evaluation of thyroid FDG uptake incidentally identified on FDG-PET/CT imaging. Nucl Med Commun (2009) 1.31
18F-FDG PET in evaluation of adrenal lesions in patients with lung cancer. J Nucl Med (2004) 1.31
In vivo detection of stem cells grafted in infarcted rat myocardium. J Nucl Med (2005) 1.30
Role of FDG-PET in the clinical management of paraneoplastic neurological syndrome: detection of the underlying malignancy and the brain PET-MRI correlates. Mol Imaging Biol (2008) 1.30
Dual time point 18F-FDG PET imaging detects breast cancer with high sensitivity and correlates well with histologic subtypes. J Nucl Med (2006) 1.28
Clinicopathologic factors associated with false negative FDG-PET in primary breast cancer. Breast Cancer Res Treat (2006) 1.27
Evolving role of molecular imaging with PET in detecting and characterizing heterogeneity of cancer tissue at the primary and metastatic sites, a plausible explanation for failed attempts to cure malignant disorders. Eur J Nucl Med Mol Imaging (2011) 1.27
Concurrent CBF and CMRGlc changes during human brain activation by combined fMRI-PET scanning. Neuroimage (2005) 1.26
Accuracy of [18F]fluorodopa positron emission tomography for diagnosing and localizing focal congenital hyperinsulinism. J Clin Endocrinol Metab (2007) 1.25
FDG-PET for diagnosing prosthetic joint infection: systematic review and metaanalysis. Eur J Nucl Med Mol Imaging (2008) 1.25
Whole-body FDG-PET imaging in the management of patients with cancer. Semin Nucl Med (2002) 1.23
Structural and functional imaging of normal bone marrow and evaluation of its age-related changes. Semin Nucl Med (2007) 1.21
Is 18F-FDG PET more accurate than standard diagnostic procedures in the detection of suspected recurrent melanoma? J Nucl Med (2004) 1.19
Retro-orbital injection is an effective route for radiopharmaceutical administration in mice during small-animal PET studies. Nucl Med Commun (2007) 1.19
Evolving role of positron emission tomography in the management of patients with inflammatory and other benign disorders. Semin Nucl Med (2004) 1.16
Role of modern imaging techniques for diagnosis of infection in the era of 18F-fluorodeoxyglucose positron emission tomography. Clin Microbiol Rev (2008) 1.16
Evaluation of 18F-FDG PET and MRI associations in pediatric diffuse intrinsic brain stem glioma: a report from the Pediatric Brain Tumor Consortium. J Nucl Med (2011) 1.14
FDG PET/CT in carcinoma of unknown primary. Eur J Nucl Med Mol Imaging (2009) 1.13
FDG-PET is an effective imaging modality to detect and quantify age-related atherosclerosis in large arteries. Eur J Nucl Med Mol Imaging (2007) 1.13
A recovery coefficient method for partial volume correction of PET images. Ann Nucl Med (2009) 1.12
FDG-PET findings in patients with suspected encephalitis. Clin Nucl Med (2004) 1.11
Diagnostic performance of FDG-PET, MRI, and plain film radiography (PFR) for the diagnosis of osteomyelitis in the diabetic foot. Mol Imaging Biol (2009) 1.11
Fluorodeoxyglucose-PET in the management of malignant melanoma. Radiol Clin North Am (2005) 1.10
Intense fluorodeoxyglucose activity in pulmonary amyloid lesions on positron emission tomography. Clin Nucl Med (2003) 1.10
Comment on: "Tumor aggressiveness and patient outcome in cancer of the pancreas assessed by dynamic 18F-FDG PET/CT". J Nucl Med (2013) 1.10
Incidental inflammatory findings in nerves and in patients with neoplastic diseases evaluated by 18F-FDG-PET/CT. Hell J Nucl Med (2009) 1.10
Functional imaging of cancer with emphasis on molecular techniques. CA Cancer J Clin (2007) 1.10
Underestimated role of 18F-FDG PET for HCC evaluation and promise of 18F-FDG PET/MR imaging in this setting. J Nucl Med (2013) 1.09
18FDG-positron emission tomography (PET) has a role to play in the diagnosis and therapy of infective endocarditis and cardiac device infection. Int J Cardiol (2013) 1.09
Impact of dual-time-point (18)F-FDG PET imaging and partial volume correction in the assessment of solitary pulmonary nodules. Eur J Nucl Med Mol Imaging (2007) 1.08
PET/MR imaging: technical aspects and potential clinical applications. Radiology (2013) 1.08
18F-FDG PET for evaluation of the treatment response in patients with gastrointestinal tract lymphomas. J Nucl Med (2004) 1.08
Clinical applications of fluorodeoxyglucose--positron emission tomography in the management of malignant melanoma. Curr Opin Oncol (2005) 1.07
18F-FDG-PET/CT in predicting pathologic complete response after neoadjuvant chemotherapy: the early metabolic response is the answer. Eur J Cancer (2013) 1.06
Complementary roles of whole-body diffusion-weighted MRI and 18F-FDG PET: the state of the art and potential applications. J Nucl Med (2010) 1.06
Retracted Neuroradiological advances detect abnormal neuroanatomy underlying neuropsychological impairments: the power of PET imaging. Eur J Nucl Med Mol Imaging (2013) 1.06
Assessment of age-related changes in abdominal organ structure and function with computed tomography and positron emission tomography. Semin Nucl Med (2007) 1.06
Novel quantitative techniques for assessing regional and global function and structure based on modern imaging modalities: implications for normal variation, aging and diseased states. Semin Nucl Med (2007) 1.06
FDG uptake in intercostal muscles is an indicator of severe respiratory disease. Clin Nucl Med (2004) 1.05
A new dimension of FDG-PET interpretation: assessment of tumor biology. Eur J Nucl Med Mol Imaging (2011) 1.04
18F FDG uptake in the large arteries: a correlation study with the atherogenic risk factors. Semin Nucl Med (2002) 1.04
PET imaging of oncogene overexpression using 64Cu-vasoactive intestinal peptide (VIP) analog: comparison with 99mTc-VIP analog. J Nucl Med (2004) 1.04
FDG positron emission tomography in the surveillance of hepatic tumors treated with radiofrequency ablation. Clin Nucl Med (2003) 1.03
Fluorodeoxyglucose-PET in characterizing solitary pulmonary nodules, assessing pleural diseases, and the initial staging, restaging, therapy planning, and monitoring response of lung cancer. Radiol Clin North Am (2005) 1.03
Gd(3+)-DTPA-DG: novel nanosized dual anticancer and molecular imaging agent. Int J Nanomedicine (2011) 1.03
123I-ADAM binding to serotonin transporters in patients with major depression and healthy controls: a preliminary study. J Nucl Med (2005) 1.02
Demonstration of excessive metabolic activity of thoracic and abdominal muscles on FDG-PET in patients with chronic obstructive pulmonary disease. Clin Nucl Med (2005) 1.02
Current status of sentinel lymph-node biopsy in patients with breast cancer. Eur J Nucl Med Mol Imaging (2010) 1.02
Utility of fluorodeoxyglucose-PET imaging in the management of patients with Hodgkin's and non-Hodgkin's lymphomas. Radiol Clin North Am (2004) 1.02
Unparalleled contribution of 18F-FDG PET to medicine over 3 decades. J Nucl Med (2008) 1.02
F-18 FDG positron emission tomography in non-Hodgkin lymphoma of the breast. Clin Nucl Med (2005) 1.02
Clinical utility of FDG-PET and PET/CT in non-malignant thoracic disorders. Mol Imaging Biol (2011) 1.01
Dynamic imaging in mild traumatic brain injury: support for the theory of medial temporal vulnerability. Arch Phys Med Rehabil (2002) 1.01
Partial volume correction of standardized uptake values and the dual time point in FDG-PET imaging: should these be routinely employed in assessing patients with cancer? Eur J Nucl Med Mol Imaging (2007) 1.01
Persistent non-specific FDG uptake on PET imaging following hip arthroplasty. Eur J Nucl Med Mol Imaging (2002) 1.00
Standardized uptake values of normal breast tissue with 2-deoxy-2-[F-18]fluoro-D: -glucose positron emission tomography: variations with age, breast density, and menopausal status. Mol Imaging Biol (2006) 0.99
Intense esophageal FDG activity caused by Candida infection obscured the concurrent primary esophageal cancer on PET imaging. Clin Nucl Med (2005) 0.99
Fundamentals of PET and PET/CT imaging. Ann N Y Acad Sci (2011) 0.99
Incidental detection of colon cancer by FDG positron emission tomography in patients examined for pulmonary nodules. Clin Nucl Med (2002) 0.99
SUVmax of 2.5 should not be embraced as a magic threshold for separating benign from malignant lesions. Eur J Nucl Med Mol Imaging (2013) 0.99
PET imaging for differentiating recurrent brain tumor from radiation necrosis. Radiol Clin North Am (2005) 0.99
Prognostic implication of dual-phase PET in adenocarcinoma of the lung. J Nucl Med (2010) 0.99
Cerebral blood flow differences between long-term meditators and non-meditators. Conscious Cogn (2010) 0.99
New treatments and imaging strategies in degenerative disease of the intervertebral disks. Radiology (2012) 0.99